来特莫韦预防异基因造血干细胞移植后巨细胞病毒感染的启动时机与疗程的真实世界研究
该研究回顾性分析97例接受来特莫韦作为原发性预防的异基因造血干细胞移植受者,按启动时机(第0天、+7天、+14天)和预防疗程(100天 vs 200天)分组。结果发现更早启动与更低的100天CMV DNA血症/临床显著CMV感染累积发生率、更晚的首次CMV DNA检出及更短DNA血症持续时间相关;200天疗程较100天疗程减少停药后晚期CMV再激活,1年总生存率在数值上更高但无统计学差异。
要点
- 更早启动来特莫韦(第0天 vs +7天 vs +14天)与更低的100天CMV DNA血症/临床显著CMV感染累积发生率相关。
- 200天疗程较100天疗程显著降低随访期间停药后晚期CMV再激活(21.6% vs 0%),且未增加严重慢性GVHD或≥3级药物相关不良事件。
- 更早启动和更长疗程的来特莫韦预防在allo-HSCT后值得进一步评估。
核心结论
- 真实世界数据提示更早启动来特莫韦预防与更低的100天CMV DNA血症/临床显著CMV感染累积发生率相关。
- 200天疗程较100天疗程减少晚期CMV再激活,1年总生存率在数值上更高但无统计学差异。
研究设计与样本
- 回顾性真实世界研究,纳入97例接受来特莫韦作为原发性预防的异基因造血干细胞移植受者。
- 按启动时机分为第0天(31例)、+7天(44例)、+14天(22例)三组;按疗程分为100天(51例)和200天(46例)两组。
主要发现
- 100天CMV DNA血症/临床显著CMV感染累积发生率:第0天组6.5%,+7天组18.2%,+14天组36.4%(Gray's test p=0.008)。
- 首次CMV DNA检出中位时间:第0天组78天,+7天组54天,+14天组36天(p=0.005)。
- 100天组与200天组相比,随访期间停药后晚期CMV再激活发生率分别为21.6%和0%(p<0.001)。
- 1年总生存率:100天组80.4%(95%CI 66.6-88.9),200天组93.5%(95%CI 81.1-97.8),log-rank p=0.103。
- 两组严重慢性GVHD或≥3级药物相关不良事件无增加。
临床怎么用
- 在allo-HSCT后考虑更早启动来特莫韦预防可能降低早期CMV DNA血症/临床显著CMV感染风险。
- 延长来特莫韦预防至200天可能减少停药后晚期CMV再激活,但需权衡个体化评估。
局限性
- 回顾性单中心研究,样本量有限(97例),结果需前瞻性研究验证。
- 启动时机和疗程分组非随机,存在混杂因素可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cytomegalovirus (CMV) reactivation is a frequent complication after allogeneic haematopoietic stem cell transplantation (allo-HSCT), but the timing and duration of letermovir prophylaxis in routine practice remain uncertain. We retrospectively reviewed 97 allo-HSCT recipients who received letermovir as primary prophylaxis, focusing on CMV-related outcomes, transplant complications, survival and safety. Letermovir was initiated on day 0 in 31 patients, on day +7 in 44 patients, and on day +14 in 22 patients. The cohort was also stratified by prophylaxis duration, with 51 patients receiving 100-day prophylaxis and 46 patients receiving 200-day prophylaxis. Earlier initiation was associated with a lower 100-day cumulative incidence (CIR) of CMV DNAemia/csCMVi (6.5% vs. 18.2% vs. 36.4%; Gray's test p = 0.008), later first CMV deoxyribonucleic acid (DNA) detection (median 78 vs. 54 vs. 36 days; p = 0.005) and a shorter duration of DNAemia. Compared with the 200-day group, the 100-day group had more late CMV reactivation after discontinuation during follow-up (21.6% vs. 0%; p < 0.001) and numerically lower 1-year overall survival (80.4% [95% confidence interval (CI), 66.6-88.9] vs. 93.5% [95% CI, 81.1-97.8]; log-rank p = 0.103), without more severe chronic graft-versus-host disease or grade ≥3 drug-related adverse events. These real-world findings suggest that both earlier initiation and longer letermovir prophylaxis deserve further evaluation after allo-HSCT.
引用
- Chen S, Su Z, Zhang X, et al. A real-world study on different initiation times and treatment durations of letermovir for cytomegalovirus prophylaxis after allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2026. PMID: 42437674. doi:10.1111/bjh.70655
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。